Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy

BACKGROUND: Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet‐derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR is a two‐part, single‐arm, dose escalation and expansion study designed to evalu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: George, Suzanne, Jones, Robin L., Bauer, Sebastian, Kang, Yoon‐Koo, Schöffski, Patrick, Eskens, Ferry, Mir, Olivier, Cassier, Phillipe A., Serrano, Cesar, Tap, William D., Trent, Jonathan, Rutkowski, Piotr, Patel, Shreyaskumar, Chawla, Sant P., Meiri, Eval, Gordon, Michael, Zhou, Teresa, Roche, Maria, Heinrich, Micahel C., von Mehren, Margaret
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2021
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018324/
https://ncbi.nlm.nih.gov/pubmed/33453089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13674
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares